Curium, a leading figure in the global nuclear medicine sector, has proudly announced the successful completion of patient enrollment in the pivotal Phase 3 ECLIPSE trial. This significant accomplishment represents a major leap forward in the quest to treat metastatic castration-resistant prostate cancer.

ECLIPSE Trial: A Study in Progress

The ECLIPSE trial, a Phase 3, multi-center, open-label, and randomized clinical trial, focuses on comparing the safety and efficacy of 177Lu-PSMA I&T against hormone therapy. The trial, involving over 400 patients across 51 sites in the United States and Europe, has reached its enrollment goal ahead of schedule, showcasing the collaborative efforts of patients, trial investigators, and clinical research partners.

Commitment to Advancing Cancer Treatment

Sakir Mutevelic, Chief Medical Officer at Curium, expressed gratitude to all involved in the trial and anticipation for the study results. Michael Patterson, CEO of Curium, North America, reiterated Curium’s commitment to advancing radioligand treatment options for prostate cancer patients. He emphasized Curium’s proven ability to manufacture and distribute nuclear medicine products globally.

Radioligand Treatment and Global Impact

Curium’s expertise in reliably producing and distributing nuclear medicine is central to its mission. The ECLIPSE trial’s progress is poised to contribute significantly to the scientific understanding of metastatic castration-resistant prostate cancer, benefiting oncologists, radiation oncologists, and urologists worldwide.

The successful enrollment in the ECLIPSE trial by Curium marks a pivotal moment in the field of oncology, potentially transforming the landscape of metastatic prostate cancer treatment and nuclear medicine.

  177Lu-PSMA I&T, Curium, Oncology, Prostate cancer, Sakir Mutevelic